Pharmacokinetics and Safety of Ripretinib in Participants with Hepatic Impairment: A Phase 1 Study
On the basis of the known safety profile of ripretinib, these increased ripretinib and combined ripretinib + DP-5439 exposures in participants with hepatic impairment are unlikely to be clinically relevant. Therefore, no dose adjustments are recommended for patients with gastrointestinal stromal tumor and hepatic impairment.
Authors
- Lakshmi Viswanathan
- Rodrigo Ruiz‐Soto (ORCID: https://orcid.org/0000-0003-3057-7735)
- Anna Papinska
- Farida Abane
- Qiang Lü (ORCID: https://orcid.org/0009-0001-9287-8333)
- Charles M. Psoinos
Institutions
- Deciphera Pharmaceuticals (United States) (US)
Publication Details
- Journal
- Advances in Therapy
- Published
- 2025-07-20
- DOI
- https://doi.org/10.1007/s12325-025-03307-3
- Primary Topic
- Liver Diseases and Immunity
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Deciphera Pharmaceuticals